| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-05-08 | Oncobiologics (USA - NJ) Zhejiang Huahai Pharmaceuticals (China) | biosimilar versions of Humira®, Rituxan®, Avastin®, and Herceptin® | development manufacturing production commercialisation |
Cancer - Oncology - Autoimmune diseases | Development agreement | |
| 2013-05-07 | DBV Technologies (France) Mount Sinai Hospital (USA) | epicutaneous immunotherapy (EPIT®) | food allergy | R&D |
Allergic diseases | R&D agreement |
| 2013-05-06 | Vivalis (France) undisclosed human vaccine developer | EB66® cell line | licensing |
Infectious diseases | Licensing agreement | |
| 2013-05-03 | Regeneron Pharmaceuticals (USA) Sanofi (France) | antibodies targeting the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications and to antibodies targeting the ANG2 (angiopoietin2) receptor and ligand in ophthalmology | acquisition |
Ophtalmological diseases | Product acquisition | |
| 2013-05-02 | Algeta (Norway) Lumiphore (USA) | Lumi4® bi-functional chelator technology | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-05-02 | Redx Pharma (UK) Pharmascience (Canada) | cFMS cancer program | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-05-01 | Tolero Pharmaceuticals (USA - UT) Sanofi (France) | alvocidib (flavopiridol) | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-04-30 | Evotec (Germany) Dana Farber Cancer Institute (USA - MA) | cancer treatments based on epigenetic drug mechanisms | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-04-30 | Glide Pharma (UK) Pfenex (Australia) | recombinant Protective Antigen (rPA) from Bacillus anthracis | anthrax | collaboration |
Infectious diseases | Collaboration agreement |
| 2013-04-30 | Ligand Pharmaceuticals (USA) Selexis (Switzerland) | 15 biologic development programs | acquisition |
Cancer - Oncology - Inflammatory diseases - Autoimmune diseases | Pipeline acquisition | |
| 2013-04-29 | Heptares Therapeutics (UK) Takeda Pharmaceutical (Japan) | G-protein coupled receptor (GPCR) | central nervous system disorders | R&D |
CNS diseases | R&D agreement |
| 2013-04-29 | GSK (UK) Impax Pharmaceuticals (USA - CA) | IPX066 (known as RYTARY™ in the U.S.) | symptomatic treatment of adult patients with idiopathic Parkinson’s disease | development |
Neurodegenerative diseases - CNS diseases | Development agreement |
| 2013-04-29 | UvA Holding (The Netherlands) Batavia Bioservices (The Netherlands) | STEP™ technology | licensing |
Technology - Services | Licensing agreement | |
| 2013-04-29 | Emisphere Technologies (USA - NJ) Novo Nordisk (Denmark) | new oral formulations of GLP-1 receptor agonists | type 2 diabetes | development |
Metabolic diseases | Development agreement |
| 2013-04-29 | UCB (Belgium) Unither Pharmaceuticals (France) | manufacturing plant in Rochester | Plant acquisition | |||
| 2013-04-23 | AstraZeneca (UK) Alchemia (Australia) | small molecules against multiple AstraZeneca targets | collaboration |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Infectious diseass - Respiratory diseases - CNS diseases | Collaboration agreement | |
| 2013-04-23 | GSK (UK) Avalon Venture (USA - CA) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2013-04-23 | Genentech, a member of Roche group (USA - Switzerland) - Institut Gustave Roussy - IGR (France) | phase 1 and phase 2 clinical trials | R&D clinical research |
Cancer - Oncology | ||
| 2013-04-22 | Antitope (UK) Research Corporation Technologies (USA - AZ) | toxic protein warhead for the next generation of antibody-drug-conjugates | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-04-22 | Kymab (UK) Novo Nordisk (Denmark) | therapeutic antibodies | undisclosed | R&D |
undisclosed | R&D agreement |
